Aclaris Therapeutics (NASDAQ: ACRS) — Company Overview, News & Financial Data
Aclaris Therapeutics develops novel dermatological therapies to address immuno-inflammatory skin conditions.
Aclaris Therapeutics
Aclaris Therapeutics (NASDAQ:ACRS) specializes in developing novel drug candidates and therapies in dermatology and immunology. The company focuses on addressing unmet needs for patients with conditions stemming from immuno-inflammatory responses. Aclaris is actively involved in a range of projects, emphasizing innovation in the treatment of skin diseases and hair loss, among other health concerns. Their objectives include advancing their pipeline products through clinical trials with the goal of achieving market approval and creating effective treatments that improve patients' quality of life. Through rigorous research and development efforts, Aclaris aims to bring transformative therapies to the market, targeting conditions with significant patient impact.
Snapshot
Operations
Products and/or services of Aclaris Therapeutics
- ATI-450, an oral MK2 inhibitor for treating rheumatoid arthritis.
- A-101 45% Topical Solution for common warts (verruca vulgaris).
- ATI-1777, an investigational soft JAK 1/3 inhibitor applied topically for atopic dermatitis.
- ATI-2138, an oral ITK inhibitor for T-cell mediated diseases, including psoriasis.
Aclaris Therapeutics executive team
- Neal S. WalkerCo-Founder, CEO & Chairman
- Hugh M. DavisPresident, COO & Director
- Kevin BalthaserChief Financial Officer
- James LoeropChief Business Officer
- Roland KolbeckChief Scientific Officer
- William C. RobertsSenior Vice President of Corporate Communications & Investor Relations
- Matthew RothmanGeneral Counsel & Corporate Secretary
- Steve TuckerExecutive Vice President of Project Leadership
- Jesse W. HallChief Medical Officer
- Nina SamraSenior Vice President of Clinical Operations
Key financials
Reported results for Aclaris Therapeutics, in USD.
- Market cap
- 588.9M
- Revenue (TTM)
- 8.2M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.6
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 7.8M | -76.4M | -64.9M | |
| 18.7M | -141.9M | -132.1M | |
| 31.2M | -97.4M | -88.5M | |
| 29.8M | -89.9M | -86.9M |